eisai biogen - Search News

Eisai, Biogen and drug

Hosted on MSN · 1d

EU regulator completes safety review of Eisai-Biogen's Alzheimer's drug without changes

The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's drug Leqembi without finding the need for any changes to the drug's status.

Business Insider · 1d

Biogen, Eisai confirm CHMP positive opinion for lecanemab

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has

MarketWatch · 1d

Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi.

Hosted on MSN · 1d

EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's drug, Leqembi, after concluding a safety review. The European Medicines Agency (EMA) in late January said the European Commission had requested a review of additional safety information for the drug,

Business Insider · 1d

Biogen, Eisai announces CHMP of EMA reaffirmed positive opinion of lecanemab

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA,

CHMP again backs Leqembi amid flurry of approval recommendations

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

More layoffs coming to NJ’s pharma sector

Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...

1d

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Eisai to part ways with 121 employees amid new US restructuring effort

Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...

Cassava’s Stock Rises After Licensing Seizure Rights for Embattled Drug Simufilam

The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its ...

2d

Mpox still a health emergency, says WHO

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results